NR (Nicotinamide Riboside).

Nicotinamide riboside raises NAD+, which sirtuin enzymes consume as a required co-substrate to do their work, while resveratrol is a widely studied activator of those same sirtuins. One supplies the fuel the enzymes run on and the other engages the enzymes, so they act on different steps of the same pathway.

The NADH that nicotinamide riboside helps generate donates its electrons to complex I of the mitochondrial electron transport chain, and coenzyme Q10 is the carrier that accepts those electrons and passes them down the chain. The two therefore sit one after the other in the same energy-producing sequence that turns nutrients into ATP.

CD38 is the main enzyme that breaks down NAD+ and its NMN intermediate in the body, and apigenin inhibits CD38 in laboratory studies. Pairing it with nicotinamide riboside works from both sides, adding NAD+ precursor while slowing the enzyme that clears the pool.

Nicotinamide riboside is phosphorylated to NMN and then adenylylated to NAD by the salvage route. It is one step upstream of the coenzyme itself.

Surplus nicotinamide is cleared by nicotinamide N-methyltransferase, which spends a methyl group from S-adenosylmethionine. Betaine restores methionine and so replenishes that donor pool.

Methylfolate feeds the remethylation of homocysteine that regenerates the methyl donor pool nicotinamide clearance draws on. It supports the same cycle betaine does, by the folate arm.

Methionine synthase needs B12 to move a methyl group from folate onto homocysteine. Without it the methyl pool that handles nicotinamide disposal turns over slowly.

Sirtuins consume NAD as a co-substrate, and pterostilbene is used as the sirtuin-side partner to the NAD-side precursor. The two sit on either side of one enzyme reaction.

NR is converted to NMN before becoming NAD, so the two feed one pathway at adjacent steps. Combining them raises the same pool rather than adding a separate route.

Nicotinamide enters NAD salvage through NAMPT while NR bypasses that step, so the two overlap in output. Nicotinamide also acts back on sirtuins as a product inhibitor, which is why the forms are usually chosen rather than stacked.

Tryptophan builds NAD from scratch through the kynurenine route, independent of the salvage route NR uses. The two supply the same coenzyme by different entry points.

S-adenosylmethionine is the actual methyl donor spent when excess nicotinamide is methylated for disposal. Supplying it directly addresses the same demand betaine covers indirectly.

A human study gave nicotinamide together with pyridoxine and reported changes in muscle stem cell activity and regeneration measures. That trial used nicotinamide rather than nicotinamide riboside, so the read-across to NR is by shared destination in the NAD pool and not by direct testing. It is the closest human pairing evidence in this candidate set and should be read that way.

NR enters the NAD pool when NRK1 or NRK2 adds a phosphate to it, and that transfer runs on ATP complexed with magnesium. Magnesium is the counter-ion the kinase needs, which puts it structurally upstream of the whole salvage step. This describes the pathway rather than predicting an added effect from co-supplementation.

NR bypasses the earliest steps of NAD assembly, but the pathway it feeds still relies on glutamine as the nitrogen donor at the amidation step when nicotinic acid intermediates are involved. Glutamine is plentiful in most diets, so this is a stated dependency rather than a gap to fill. It explains why NAD synthesis is a multi-input process.

Whatever raises the NAD pool only helps if NADH can be handed on, and the first acceptor is the flavin mononucleotide site of complex I, which is built from riboflavin. The two vitamins sit on consecutive links of the same electron chain. A larger NAD pool with a constrained flavin step does not move flux.

NAD levels reflect production and consumption, and CD38 is one of the larger consumers, particularly with age. Flavonoids including quercetin and apigenin have been described as CD38 inhibitors in laboratory work, which is the rationale for pairing them with a precursor. The inhibition data is preclinical, and whether it changes tissue NAD in people who take both is unresolved.

Lipoic acid cycles between reduced and oxidised states, and the enzyme that regenerates it hands electrons directly to NAD. Supplemental lipoate therefore interacts with the same redox pool an NAD precursor is aimed at. Read this as a mechanistic overlap rather than a measured combined effect.

Glutathione turnover has two separate constraints: enough cysteine to make it and enough NADPH to keep recycling it. NAC covers the first and an NAD precursor sits upstream of the second. The two are formulated together for that reason; the pairing itself has not been tested here.

Pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase both need thiamine pyrophosphate and both hand their electrons to NAD. Thiamine also drives the transketolase steps that generate NADPH-linked pentose flux. The two vitamins are joint inputs to the same reactions rather than independent additions.

Creatine buffers ATP over seconds through phosphocreatine, while NAD availability affects the slower oxidative regeneration of ATP. The two act on different timescales in the same tissue, which is the rationale for stacking them in muscle-support formulas. No combination data is being cited and the additive claim is a hypothesis.

Urolithin A is described as promoting removal of damaged mitochondria, while an NAD precursor supplies the cofactor that sirtuin-driven mitochondrial biogenesis depends on. Clearance and supply are complementary rather than overlapping. This is a mechanistic pairing with no combination trial behind it.

Spermidine is studied as an autophagy inducer and NR as a cofactor precursor, two different levers on cellular housekeeping. They are combined in longevity-positioned formulas on that logic. The rationale is preclinical and the pairing has not been measured in people here.